Source: Eur Respir J 2005; 26: 755-758
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Johnson W. C., Raghu G.. Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures. Eur Respir J 2005; 26: 755-758

Member's Comments

No comment yet.

Related content which might interest you: Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences Source: Eur Respir Rev 2015; 24: 420-427 Year: 2015 A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials Source: Eur Respir J 2015; 46: 243-249 Year: 2015 A registry of patients with idiopathic pulmonary fibrosis in Russia: 2-yr results and therapeutic modalities in real-life practice Source: International Congress 2019 – Interstitial lung disease registries Year: 2019 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Diagnosis of idiopathic pulmonary fibrosis: from guidelines to clinical practice Source: Annual Congress 2009 - Clinical aspects of diffuse parenchymal lung disease Year: 2009 Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 58-64 Year: 2015 Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward Source: Eur Respir J 2013; 42: 1446-1448 Year: 2013 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 PROOF: A prospective observational registry to describe the disease course and outcomes of idiopathic pulmonary fibrosis patients in a real-world clinical setting in Belgium and Luxembourg: Exposure in the interim report of 175 IPF patients Source: International Congress 2016 – IPF clinical Year: 2016 The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations Source: Eur Respir J 2016; 47: 344-345 Year: 2016 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry Source: Eur Respir J 2015; 46: 186-196 Year: 2015 Idiopathic pulmonary fibrosis trials: recommendations for the jury Source: Eur Respir J 2011; 38: 1002-1004 Year: 2011 A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (1) 00096-2016; 10.1183/23120541.00096-2016 Year: 2017 Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials Source: ERJ Open Res, 5 (1) 00147-2018; 10.1183/23120541.00147-2018 Year: 2019 Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019 Year: 2019 The concept of cystic fibrosis pulmonary exacerbation in clinical medicine and as a trial end-point Source: Annual Congress 2008 - Exacerbations of chronic respiratory disease – state of the art Year: 2008 Heterogeneity of treatment response in bronchiectasis clinical trials Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Imaging of idiopathic pulmonary fibrosis based on case presentations: guidelines, pitfalls and prevention of misdiagnosis Source: Virtual Congress 2021 – Imaging grand round Year: 2021